| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Nutrient Requirements and Functions Laboratory, Beltsville Human, Nutrition Research Center, US Department of Agriculture, ARS, Beltsville, Maryland
Address reprint requests to: Richard A. Anderson, PhD, FACN, USDA, ARS, BHNRC, NRFL, Bldg 307, Rm. 224, BARC-East, Beltsville, MD 20705-2350
Within the last 5 years chromium (Cr) has been shown to play a role in glucose intolerance, Type 2 diabetes mellitus (Type 2 DM), and gestational diabetes. In addition, diabetes and the neuropathy of a patient on home parenteral nutrition were alleviated when supplemental Cr was added to total parenteral nutrition (TPN) solutions. In a study conducted in China that has been supported by studies in the United States, supplemental Cr as Cr picolinate improved the blood glucose, insulin, cholesterol, and hemoglobin A1C in people with Type 2 DM in a dose dependent manner. Follow-up studies of >1 year have confirmed these studies. The requirement for Cr is related to the degree of glucose intolerance: 200 µg/day of supplemental Cr is adequate to improve glucose variables of those who are mildly glucose intolerant. However, people with more overt impairments in glucose tolerance and diabetes usually require more than 200 µg/day. Daily intake of 8 µg of Cr per kg body weight was also more effective than 4 µg/kg in women with gestational diabetes. The mechanism of action of Cr involves increased insulin binding, increased insulin receptor number, and increased insulin receptor phosphorylation. In summary, supplemental Cr has been shown to have beneficial effects without any documented side effects on people with varying degrees of glucose intolerance ranging from mild glucose intolerance to overt Type 2 DM.
Key words: chromium, diabetes, glucose tolerance, trace elements, insulin
This article has been cited by other articles:
|
|
 |
|
  F. Dong, M. R. Kandadi, J. Ren, and N. Sreejayan Chromium (D-phenylalanine)3 Supplementation Alters Glucose Disposal, Insulin Signaling, and Glucose Transporter-4 Membrane Translocation in Insulin-Resistant Mice J. Nutr., October 1, 2008; 138(10): 1846 - 1851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Via, C. Scurlock, J. Raikhelkar, G. D. Luozzo, and J. I. Mechanick Chromium Infusion Reverses Extreme Insulin Resistance in a Cardiothoracic ICU Patient Nutr Clin Pract, June 1, 2008; 23(3): 325 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rink, S. Roy, S. Khanna, T. Rink, D. Bagchi, and C. K. Sen Transcriptome of the subcutaneous adipose tissue in response to oral supplementation of type 2 Leprdb obese diabetic mice with niacin-bound chromium Physiol Genomics, November 21, 2006; 27(3): 370 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Guallar, F. J. Jimenez, P. van 't Veer, P. Bode, R. A. Riemersma, J. Gomez-Aracena, J. D. Kark, L. Arab, F. J. Kok, J. M. Martin-Moreno, et al. Low Toenail Chromium Concentration and Increased Risk of Nonfatal Myocardial Infarction Am. J. Epidemiol., July 15, 2005; 162(2): 157 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. T. Cefalu and F. B. Hu Role of Chromium in Human Health and in Diabetes Diabetes Care, November 1, 2004; 27(11): 2741 - 2751. [Full Text] [PDF]
|
|
|
|
|
|
S. Rajpathak, E. B. Rimm, T. Li, J. S. Morris, M. J. Stampfer, W. C. Willett, and F. B. Hu Lower Toenail Chromium in Men With Diabetes and Cardiovascular Disease Compared With Healthy Men Diabetes Care, September 1, 2004; 27(9): 2211 - 2216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Frauchiger, C. Wenk, and P. C. Colombani Effects of Acute Chromium Supplementation on Postprandial Metabolism in Healthy Young Men J. Am. Coll. Nutr., August 1, 2004; 23(4): 351 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S Kalman Chromium picolinate and type 2 diabetes Am. J. Clinical Nutrition, July 1, 2003; 78(1): 192 - 192. [Full Text] [PDF]
|
|
|
|
|
|
M. D Althuis, N. E Jordan, E. A Ludington, and J. T Wittes Glucose and insulin responses to dietary chromium supplements: a meta-analysis Am. J. Clinical Nutrition, July 1, 2002; 76(1): 148 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Behall, J. C. Howe, and R. A. Anderson Apparent Mineral Retention Is Similar in Control and Hyperinsulinemic Men after Consumption of High Amylose Cornstarch J. Nutr., July 1, 2002; 132(7): 1886 - 1891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. T. Cefalu, Z. Q. Wang, X. H. Zhang, L. C. Baldor, and J. C. Russell Oral Chromium Picolinate Improves Carbohydrate and Lipid Metabolism and Enhances Skeletal Muscle Glut-4 Translocation in Obese, Hyperinsulinemic (JCR-LA Corpulent) Rats J. Nutr., June 1, 2002; 132(6): 1107 - 1114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. O'Connell Select Vitamins and Minerals in the Management of Diabetes Diabetes Spectr, August 1, 2001; 14(3): 133 - 148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Anderson, A.-M. Roussel, N. Zouari, S. Mahjoub, J.-M. Matheau, and A. Kerkeni Potential Antioxidant Effects of Zinc and Chromium Supplementation in People with Type 2 Diabetes Mellitus J. Am. Coll. Nutr., June 1, 2001; 20(3): 212 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E Gunton, G. Hams, R. Hitchman, and A. McElduff Serum chromium does not predict glucose tolerance in late pregnancy Am. J. Clinical Nutrition, January 1, 2001; 73(1): 99 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Guan, J. J. Matte, P. K. Ku, J. L. Snow, J. L. Burton, and N. L. Trottier High Chromium Yeast Supplementation Improves Glucose Tolerance in Pigs by Decreasing Hepatic Extraction of Insulin J. Nutr., May 1, 2000; 130(5): 1274 - 1279. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
